This article reviews the recent literature concerning important issues in the management of patients with bladder cancer. A brief overview of all aspects of bladder cancer including the etiology, diagnosis, and treatment are discussed with a focus on recent advances.
Introduction
Bladder cancer is the fourth most commonly diagnosed malignancy in the United States with an estimated 60,240 new cases and a projected 12,710 deaths in 2004 [1] . It is an extremely heterogeneous disease not only in terms of morphology and cancer biology but also in terms of natural history and prognosis. Currently, the tumornode-metastasis (TNM) staging system combined with tumor grade provides the most useful information to guide treatment decision-making. However, these clinicopathologic features are often inadequate to predict the optimal therapeutic regimen for the individual patient. A multimodal treatment approach should be considered for most patients with bladder cancer and may include surgery, immunotherapy or chemotherapy, and radiation therapy.
Etiology and risk factors
The major risk factors for developing bladder cancer include advanced age and exposure to arylamines. Cigarette smoking constitutes the greatest exposure risk to these carcinogens and has been estimated to be a contributing factor in up to 50% of all cases in the United States [2] . However, many of the arylamine compounds (i.e. 2,3dimethylaniline, 3,5-dimethylaniline, 3-ethylaniline) thought to play a carcinogenic role in bladder cancer have been found in significantly higher concentrations in nonsmokers who develop bladder cancer compared with controls [3 • ]. While certain at-risk occupations including those in the dye, textile, chemical, and rubber industries have been identified, they appear to represent only a small fraction of total diagnoses with many cases occurring despite no obvious exposure to carcinogens. There are likely many other environmental or occupational exposures to these compounds yet to be identified which contribute to bladder cancer in nonsmokers. In addition, susceptibility appears to be related to genetic factors that affect an individual's metabolism of these carcinogens. This helps explain why people with similar exposures to these compounds may have very different risks of developing disease.
Diagnosis
The standard methods to detect and diagnose urothelial cancer currently include cystoscopy and urine cytology followed by transurethral biopsy/resection. A variety of markers have been tested for their potential utility as diagnostic or screening tools for bladder cancer. While many markers have improved sensitivity when compared with urine cytology, few share its specificity, which approaches 100%. This topic has recently been reviewed by Dey as well as Quek et al. [4 • ,5 • ] While many of these urinary markers have shown promise, none has been proven clinically effective enough to render cystoscopy unnecessary in the evaluation of patients suspected of having bladder cancer or in the surveillance of patients with known disease.
Nonmuscle invasive bladder cancer
Approximately 70% of patients with bladder cancer initially present with superficial disease that does not invade the muscularis propria. For clinicians who manage superficial bladder cancer, individual patient risk assessment for tumor recurrence and progression should guide treatment decisions and surveillance monitoring. Treatment for these patients may include transurethral resection (TUR) alone, adjuvant intravesical chemotherapy or immunotherapy, and even potentially more aggressive therapy such as radical cystectomy.
Intravesical therapy
Patients at high risk for tumor recurrence or progression clearly benefit from intravesical therapy as an adjunct to TUR. The risk of short-term recurrence and progression can be potentially reduced or delayed with this treatment although the resultant effect on long-term recurrence and progression is less clear. Recent data has added to the body of literature that has demonstrated the superiority of bacille calmette-guerin (BCG) over mitomycin C in decreasing tumor recurrence particularly in patients with high-risk disease [6,7 • ]. Patients treated with maintenance BCG appear to benefit the most. The effect of BCG on tumor progression to muscle invasive disease has been unclear. Many studies historically have been underpowered for this endpoint. A meta-analysis by Sylvester et al. has demonstrated a significantly reduced risk of progression with BCG compared with controls [8] . Importantly, this advantage was limited to patients who received a maintenance regimen. In a more recent meta-analysis comparing 1,277 patients treated with BCG and 1,133 treated with mitomycin C, no statistically significant difference in progression was seen with a median follow-up of 26 months (7.67% vs. 9.44%, P = 0.081). However, in a subgroup analysis of those trials that included BCG maintenance therapy, BCG did confer a significant reduction in tumor progression compared with mitomycin (10.18% vs. 14.19%, P = 0.020) [9 • ]. Therefore, there is a growing body of evidence that intravesical BCG (in particular when given as a maintenance regimen) can significantly decrease the risk of tumor progression while there is little evidence this is true for mitomycin C.
Theoretically, immediate intravesical chemotherapy after TUR may prevent tumor cell implantation and recent data has suggested that a single postoperative instillation can significantly reduce tumor recurrence. There were 1,476 patients included in a meta-analysis of all randomized trials comparing TUR alone to TUR plus a single postoperative instillation of chemotherapy (within 24 hours) which confirmed the beneficial role of this concept.
The authors found a 39% decreased risk of recurrence (P < 0.0001) at a median follow up of 3.4 years in the group receiving this treatment [10 • ].
High-risk superficial bladder cancer
Patients with high-grade superficial tumors (CIS, Ta, T1) are at a substantial risk for progression to muscle invasion as well as subsequent bladder cancer mortality. Particularly at risk are patients with high-grade disease and lamina propria invasion (T1G3). A recent retrospective analysis of 153 patients with T1G3 bladder cancer has confirmed the long noted '30 percent rule' that, of those patients treated conservatively with TUR +/ÿ adjuvant BCG, 30% of patients will be recurrence-free, 30% will require delayed cystectomy, and 30% will die of disease [11] . This same group recently retrospectively compared their experience with both conservative treatment and immediate radical cystectomy in patients with primary T1G3 disease [12 • ]. The authors reported that, after excluding those with multifocal disease, 50% of patients treated with a strategy involving TUR and adjuvant BCG could remain disease-free with bladder preservation at a median follow up of 6.9 years. Serreta et al. also reported their experience in this cohort of patients [13 • ]. The authors retrospectively analyzed 137 patients with T1G3 disease who were treated with TUR followed by intravesical chemotherapy. After strict exclusion criteria of concomitant or previous carcinoma in situ (CIS), previous T1G3 tumors, prior pelvic radiation or chemotherapy, tumor size > 3 cm, and multifocal tumors (more than 3), they found a 5-year progression-free survival rate of 90%. The high success rate with conservative treatment in this study highlights the importance of selection factors which may predict a good prognosis in this group of patients.
Considering the well-documented clinical staging error in bladder cancer, understaging almost certainly contributes to the progression rate that is reported in the literature for high-grade Ta and T1 tumors. Initial TUR specimens may underestimate the actual pathologic stage in up to 30-40% of cases [14] . A second restaging TUR can substantially improve the accuracy of clinical staging and should be considered [15-17 • ]. Another problem with assessing patients based on clinical staging is that metastases can occur even in the absence of muscle invasion. Approximately 7% of patients with pathologic T1 disease have lymph node metastases at cystectomy [18] . Therefore, it is unlikely that the optimal treatment for individual patients could be predicted by clinical staging alone.
Without a doubt, the ability to stratify patients with T1G3 bladder cancer into higher and lower risk groups would be an extremely valuable tool for clinicians. Factors that may predict a higher risk of progression and poorer outcome include depth of lamina propria invasion (deep to the muscularis mucosae), tumor multifocality, and concomitant CIS [19, 20] . Studies investigating the potential prognostic role of molecular markers such as p53 are ongoing and may prove clinically useful to predict the specific biologic behavior of individual tumors. At this time, conservative management with intravesical therapy and bladder preservation or immediate cystectomy are both acceptable treatment options for select patients with T1G3 bladder cancer. Both options should be presented to these patients with an explanation of the risks and benefits of each. The final decision on treatment should then be made on an individual basis taking into account such factors as age, comorbidities, and patient preference. Patients who elect conservative management require close, life-long follow up with the potential need for delayed cystectomy.
Muscle invasive bladder cancer
While most patients with bladder cancer have superficial disease, 20-40% will either present with or progress to muscle invasive cancer [18] . If untreated, fewer than 15% of patients with muscle-invasive bladder cancer survive 2 years [21] . Aggressive treatment with surgery, radiation, and/or chemotherapy is therefore warranted in most patients.
Surgery
The standard treatment in the U.S. for localized muscle invasive bladder cancer is radical cystectomy. Surgery is curative for most patients who have localized disease with 5-and 10-year recurrence free survival rates approaching 70% [18] . A recent multicenter, retrospective analysis from Japan of 1,131 consecutive patients undergoing radical cystectomy reported similar 5-year survival [22 • ]. This study also confirmed that pathologic stage and lymph node status are independent predictors of survival.
Lymph node metastases are present in approximately 25% of patients undergoing radical cystectomy [23,24 • ]. Aside from the surgical staging information that lymphadenectomy provides, it also provides therapeutic benefit [25] . In addition, the quality and extent of pelvic lymphadenectomy appear to significantly affect patient outcomes. Currently, no universally accepted standards for performing pelvic lymph node dissection exist.
A collaborative group from four institutions reported on their experience with radical cystectomy and lymphadenectomy in 1,091 patients over a 3-year period [26] . This report helps to establish a benchmark for what can reasonably be expected when performing radical cystectomy in terms of surgical outcome measures such as surgical margin status and number of lymph nodes resected. Importantly, multiple variables are identified which affect these surgical outcome measures. These include patient age and comorbidities, prior radiation or surgical therapy, tumor burden, and individual surgeon experience. It is well documented that a variety of factors influence the number of lymph nodes that are obtained in lymphade-nectomy specimens. These include the diligence of the pathologist to locate nodes, whether the specimen is submitted en bloc or separately, and the extent of the node dissection [24] . All of these factors have made it difficult to establish a standard surgical technique.
Extended lymph node dissections have reliably resulted in a greater number of nodes removed and examined [26 • ,27 • ,28 • ]. Recent studies have reported an association between survival and the total number of nodes removed, a lower number of total positive nodes, and a lower ratio of positive lymph nodes to total nodes removed [23 • , [29] [30] [31] . Furthermore, some studies have recently evaluated lymph node mapping in an attempt to better understand the lymphatic drainage of bladder cancer. Three studies prospectively separated lymph node packets based on anatomic location during extended pelvic lymphadenectomy [27 • ,28 • ,32 • ]. While pelvic nodes were the most common site of metastases, it was not uncommon to find patients with negative pelvic nodes and positive nodes elsewhere. In one study, 10% of solitary positive nodes were found above the bifurcation of the common iliac vessels [32 • ]. Yet, in none of these studies was a solitary positive node found above the bifurcation of the aorta. It is also important to note that even in patients with a focal unilateral tumor, bilateral lymph node metastases are not uncommon. All of these data underscore the importance of performing a bilateral extended lymph node dissection to obtain the most accurate assessment of an individual patient's lymph node status. An extended dissection has not been associated with increased morbidity and it may improve survival [33 • ]. However, only prospective randomized trials comparing a limited vs. a more extended lymphadenectomy will answer the questions of whether more accurate staging, increased surgical cure, and improved survival are associated with an extended node dissection.
Bladder preservation
Bladder-sparing approaches incorporating various combinations of TUR, radiotherapy, and systemic chemotherapy have been reported in several studies to result in overall survival rates comparable to contemporary radical cystectomy series [34] . A recent retrospective study suggests that p53 and p21 expression may be useful in selecting appropriate patients for bladder preservation [35 • ]. Overexpression of p53 and p21 individually and in combination were strong unfavorable predictors of survival with this strategy.
Neoadjuvant and adjuvant chemotherapy
Surgical therapy alone is inadequate treatment for many patients with invasive bladder cancer. Approximately 50% of patients who undergo radical cystectomy eventually present with recurrent distant disease indicating occult metastases at the time of surgery [36] . Neoadjuvant chemotherapy may benefit those patients with micrometastases prior to definitive local therapy. Recent evidence has suggested a small, yet significant survival advantage for patients who receive neoadjuvant chemotherapy [37] [38] [39] . The results from a recent meta-analysis lend further evidence to this conclusion [40 •• ] . In this study including 2,605 patients from 11 trials, there was a statistically significant 10% decreased risk of death from bladder cancer with neoadjuvant chemotherapy (P = 0.02). This benefit was primarily due to the eight trials employing combination chemotherapy. Sherif et al. combined the results from two Nordic studies which did not reach statistical significance when separately evaluated [41 • ]. With the combined data from the 620 patients in both studies, there was a significant difference with an overall 5-year survival advantage of 56% vs. 48% when neoadjuvant chemotherapy was administered.
Presently, the optimal systemic chemotherapy regimen is unknown. Methotrexate, Vinblastine, Adriamycin, and Cisplatin (MVAC) is considered by most to be the 'gold standard,' but has been associated with significant toxicity. Newer agents and combinations are currently being investigated to improve efficacy and decrease adverse effects. A phase-II trial reported the results of 50 patients who received a combination of docetaxel and cisplatin as neoadjuvant therapy prior to radical cystectomy [42 • ]. They reported a complete pathologic response in 36.6% and a 5-year survival in 60% of the 41 patients who subsequently underwent cystectomy. As in other neoadjuvant trials, the absence of residual tumor in the final pathologic specimen (complete response) was associated with improved survival (P = 0.031). This regimen was very well tolerated.
While neoadjuvant treatment offers the benefits of systemic therapy when the burden of micrometastatic disease is least and at a time when patients may be better able to tolerate treatment, there are certain disadvantages. These include the delay of definitive local therapy and the inaccuracy of using clinical staging data. Furthermore, since greater than 60% of patients with pathologically organ-confined, node-negative disease will be cured with radical cystectomy alone, a number of patients may be exposed to the risks of chemotherapy without benefit [18]. Therefore, it is of paramount importance to pre-select those patients who will derive benefit. While certain high-risk clinical data such as presence of clinical stage T3 disease, lymphovascular invasion, and prostatic stromal invasion may be useful, other methods including molecular markers may help stratify patients appropriately. Shariat et al. examined the association between p53, p21, pRB and p16 expression with outcomes in 80 bladder cancer patients who had undergone radical cystectomy [43 • ]. The authors found the p53 phenotype to be the single marker most predictive of outcome in bladder cancer.
They also found that although each of these cell cycle regulators was associated with bladder cancer outcome, the prognostic accuracy could be increased with certain combinations.
Adjuvant chemotherapy avoids the disadvantages of neoadjuvant treatment and allows a subset of patients to be selected for further treatment based on pathologic staging factors that have demonstrated prognostic value. Highrisk pathologic features such as extravesical extension or positive nodal metastases are known to be associated with worse survival [18] . Thus, these patients can be predicted to gain more from chemotherapy than those with organconfined disease. Many clinicians advocate adjuvant as opposed to neoadjuvant chemotherapy for this reason. Yet, while high-level evidence is available demonstrating the efficacy of neoadjuvant chemotherapy, it is lacking for chemotherapy administered in the adjuvant setting. Although several published series have reported a survival benefit with adjuvant treatment, they have been highly criticized for various reasons [44] . Currently, no well-designed randomized, prospective study has unequivocally demonstrated its benefit. An Intergroup study coordinated by the European Organization for Research and Treatment of Cancer is in the process of accruing subjects for a phase-III trial randomizing patients with high-risk pathologic features to receive adjuvant chemotherapy vs. delayed chemotherapy at the time of recurrence [44] . Molecular markers are also being studied to determine their potential role in selecting patients for adjuvant therapy. An ongoing trial is randomizing patients with organ-confined bladder cancer to observation versus three cycles of MVAC after cystectomy based on p53 status [44] .
Metastatic bladder cancer
The standard chemotherapy for metastatic urothelial carcinoma for more than a decade has been the multidrug regimen of MVAC. While the median survival for patients with metastatic disease is consistently reported to be greater than one year, long-term survival is rare [45] . Therefore, new and more effective treatments are needed. Over the past few years, the combination of gemcitabine and cisplatin (GC) has been increasingly used with data suggesting similar response but less toxicity when compared with MVAC [46] . GC is now accepted by many clinicians as a first-line option for treating advanced bladder cancer. Recent trials have attempted to optimize therapy by further reducing the toxicity associated with chemotherapy. The major toxicity of GC has been myelosuppression, which is found most commonly on day 15 of a 28-day cycle [46] . Hussain et al. used a 21-day schedule of GC instead of the 28-day schedule, which has been used previously [47 • ]. This phase-II study administered gemcitabine (1000 mg/m 2 ) and fractionated cisplatin (35 mg/m 2 ) on days 1 and 8 with no planned treatment on day 15. With this alternative regimen, myelosuppression was again found to be most common on day 15. However, this conveniently coincided with a day of no planned treatment. There were no clinical sequelae from myelosuppression and median survival was an encouraging 16 months.
Taxanes have also recently demonstrated activity against bladder cancer in both single agent and combination trials. The Hellenic Cooperative Oncology Group had previously reported promising results from a phase-II trial with docetaxel and cisplatin [48 •• ] . Recently, this group conducted a phase-III trial randomizing 220 patients with advanced urothelial cancer to docetaxel and cisplatin or MVAC. The authors found MVAC to be superior in terms of response (54.2% vs. 37.4%), median time to progression (9.4 vs. 6.1 months), and median survival (14.2 vs. 9.3 months) [48 •• ] .
Alternative combinations have been investigated for patients unable to receive platinum-based regimens and for those patients who have failed standard treatment. Gemcitabine/vinorelbine has been studied in a phase-II trial of 21 patients with renal impairment (Group 1) and 10 patients who did not respond to cisplatin-containing chemotherapy (Group 2) [49 • ]. In Group 1, the overall and complete response rates were 47.6% and 9.5% with a median survival of 15 months. Group 2 had only two partial responses (20%) and no complete responses and median survival was 7 months. Carboplatin has been substituted for cisplatin in studies involving similar types of patients. Linardou et al. investigated the use of gemcitabine and carboplatin in 56 patients who had an Eastern Cooperative Oncology Group performance status >2, age over 75 years, or a creatinine clearance of <50 ml/min [50 • ]. The overall response rate was 36% with a median time to progression of 4.8 months and median overall survival of 7.2 months.
Conclusions and future research
Progress continues in defining the roles of multimodality therapy for this diverse disease entity. This is expected to lead to improved quality of care for patients with bladder cancer. Molecular biology will have an ever-increasing role in all aspects of bladder cancer diagnosis and management. It is hoped that advances in this field will help guide the selection of optimal effective therapy and minimize the impact on quality of life for the individual patient. Eventually, it is likely that novel targeted therapies will enter the clinical realm for treating this disease.
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